INtegratioN of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL

Trial Profile

INtegratioN of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Feb 2017

At a glance

  • Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Capecitabine; Cisplatin; Fluorouracil
  • Indications Adenocarcinoma; Gastric cancer
  • Focus Therapeutic Use
  • Acronyms INNOVATION
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Sep 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
    • 03 Aug 2015 Planned End Date changed from 1 Dec 2021 to 1 Sep 2024 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top